Citations

Showing 10 of 108152 citations.

CORR Insights®: People Prefer to Continue with Painful Activities Even if They Lead to Earlier Surgery
Schwartz, Adam J.

Mayo Clinic

Clinical Orthopaedics & Related Research | May 3, 2021 | Volume: 479 | Issue: 9 | Pages: 1936-1938

10.1097/corr.0000000000001784 | PMID 33938482 Get It

Challenges in Diagnosis and Management of Hemobilia
Parvinian, Ahmad , Fletcher, Joel G. , Venkatesh, Sudhakar K. , Fidler, Jeff L. , Khandelwal, Ashish , Storm, Andrew C , Venkatesh, Sudhakar K , Fidler, Jeff L. , Khandelwal, Ashish R , Fletcher, Joel G , Storm, Andrew C.

Mayo Clinic

RadioGraphics | May 3, 2021 | Volume: 41 | Issue: 3 | Pages: 802-813

10.1148/rg.2021200192 | PMID 33939540 Get It

Pre- and Postprocedural CT of Transcatheter Left Atrial Appendage Closure Devices
Rajiah, Prabhakar , Thaden, Jeremy J. , Foley, Thomas A. , Williamson, Eric E. , Ranganath, Praveen , Foley, Thomas , Ranganath, Praveen , Rajiah, Prabhakar , Alkhouli, Mohamad

Mayo Clinic

RadioGraphics | May 3, 2021 | Volume: 41 | Issue: 3 | Pages: 680-698

10.1148/rg.2021200136 | PMID 33939541 Get It

DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma
Yang, Ju Dong , Ghoz, Hassan , Aboelsoud, Mohammed M., Yab, Tracy C. , Cao, Xiaoming , Giama, Nasra H., Moser, Catherine D., Smyrk, Thomas C. , Kipp, Benjamin R. , Roberts, Lewis R. , Berger, Calise K. , Foote, Patrick H. , Barr Fritcher, Emily G, Mahoney, Douglas W. , Kisiel, John B , Roberts, Lewis R , Yang, Ju Dong , Taylor, William R. , Fritcher, Emily G. Barr , Gores, Gregory J. , Kisiel, John B.

Mayo Clinic

Hepatology Communications | May 3, 2021 | Volume: 5 | Issue: 8 | Pages: 1448-1459

10.1002/hep4.1730 | PMID 34430788 Get It

Cholangiocarcinoma (CCA) has poor prognosis due to late‐stage, symptomatic presentation. Altered DNA methylation markers may improve diagnosis of CCA. Reduced‐representation bisulfite sequencing was performed on DNA extracted from frozen CCA tissues and matched to adjacent benign biliary epithelia or liver parenchyma. Methylated DNA markers (MDMs) identified from sequenced differentially methylated regions were selected for biological validation on DNA from independent formalin‐fixed, paraffin‐embedded CCA tumors and adjacent hepatobiliary control tissues using methylation‐specific polymerase chain reaction. Selected MDMs were then blindly assayed on DNA extracted from independent archival biliary brushing specimens, including 12 perihilar cholangiocarcinoma, 4 distal cholangiocarcinoma cases, and 18 controls. Next, MDMs were blindly assayed on plasma DNA from patients with extrahepatic CCA (eCCA), including 54 perihilar CCA and 5 distal CCA cases and 95 healthy and 22 primary sclerosing cholangitis controls, balanced for age and sex. From more than 3,600 MDMs discovered in frozen tissues, 39 were tested in independent samples. In the clinical pilot of 16 MDMs on cytology brushings, methylated EMX1 (empty spiracles homeobox 1) had an area under the curve (AUC) of 0.98 (95% confidence interval [CI], 0.95‐1.0). In the clinical pilot on plasma, a cross‐validated recursive partitioning tree prediction model from nine MDMs was accurate for de novo eCCA (AUC, 0.88 [0.81‐0.95]) but not for primary sclerosing cholangitis–associated eCCA (AUC, 0.54 [0.35‐0.73]). Conclusion : Next‐generation DNA sequencing yielded highly discriminant methylation markers for CCA. Confirmation of these findings in independent tissues, cytology brushings, and plasma supports further development of DNA methylation to augment diagnosis of CCA.
633 Dysregulated REM Sleep in Children with Moebius syndrome
Edlund, Wendy , Kotagal, Suresh

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A248-A248

10.1093/sleep/zsab072.631 Get It

Abstract Introduction Moebius syndrome (MBS) is a rare disorder characterized by failure of development of the 6th and 7th cranial nerve nuclei located in the pons. Though the congenital lesion abuts the pontine tegmentum, sleep architecture has not been evaluated in MBS. Methods We report the clinical features of three children with MBS, and discuss implications for “developmental” RBD. Results Three clinically and MRI brain scan-confirmed MBS children, age 0.5 to 16 years, mean 8.5 ± 6.3 years, were evaluated for disrupted sleep, with repetitive crying (1/3), yelling (2/3), agitation in sleep (2/3), and injuring a co-sleeping sibling (1/3); 3/3 had REM sleep without atonia while 2/3 had RBD. REM sleep was reduced in all three: 21.7% in the infant (reference REM percentage value in infancy is about 40%), 11.4% in subject 2 and 3% in subject 3. Treatment with clonazepam (patients 2 and 3) or melatonin (patient 1) had variable results. Conclusion Children with Moebius syndrome have both quantitative (reduced percentage) and qualitative abnormalities of REM sleep (RSWA/RBD). The association of MBS with RSWA/RBD suggests more extensive involvement than published in literature, with extension into the sub-laterodorsal pontine tegmentum and “REM-off” neurons. Moebius syndrome might serve as a model for study of “developmental” REM sleep behavior disorder. Support (if any):
743 Differences in the prevalence of sleep disturbance and associated risk factors in alcohol use disorders and major depression
Kolla, Bhanu Prakash , Coombes, Brandon J. , Mansukhani, Meghna P. , Biernacka, Joanna M.

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A290-A290

10.1093/sleep/zsab072.740 Get It

Abstract Introduction Sleep disruption is common in patients with alcohol use disorders (AUD) and major depressive disorders (MDD). Our understanding of the differences in the rates of sleep disturbance and overall sleep duration in patients with AUD, MDD, and comorbid AUD and MDD is limited. Furthermore, it is unknown whether there is variation in demographic and clinical characteristics associated with sleep disturbance and duration in these diagnostic groups. Methods This study utilized data from the UK Biobank (UKB). Depression status was determined based on review of International Classification of Diseases (ICD) codes and health records. AUD status was based on AUDIT scores (score ≥8 was defined as AUD) and sleep disturbance was evaluated utilizing a self-reported questionnaire. The sample was categorized into those with MDD alone (MDD+/AUD-)(n=18,154), AUD alone (MDD-/AUD+)(n=6123), both (MDD+/AUD+)(n=9027), and controls with neither (MDD-/AUD-)(n=27,573). We used generalized linear models (GLMs) to compare rates of sleep disruption and duration among the groups and determine the clinical predictors of sleep disturbance/duration in the four groups as well as test whether these factors differed among the groups. Results The prevalence of sleep disturbance in the control sample (MDD-/AUD-) was 26.4% and the self-reported sleep duration in this sample was 7.209±0.919. Subjects with AUD and/or MDD had greater rates of sleep disturbance and shorter sleep duration. Among the different diagnostic categories, the prevalence of sleep disturbance was highest in subjects with MDD+/AUD+ (36.5%) followed by those with MDD+/AUD- (35.6%) and MDD-/AUD+ (27.9%)(all p<0.0001). Similarly, the sleep duration was shortest in subjects with MDD+/AUD+ (7.143±1.016), followed by MDD+/AUD- (7.158±1.050) and by MDD-/AUD+ (7.202±0.891)(all p<0.0001). Subjects with sleep disturbance were more likely to be older, female, and with higher body mass index, Townsend deprivation index, and neuroticism scores across all four groups (all p<0.05). Conclusion In a large population-based cohort, MDD with and without comorbid AUD was associated with greater rates of sleep disturbance and shorter sleep duration than AUD alone. The clinical and demographic factors associated with sleep disturbance did not differ in these diagnostic categories, indicating possible similar underlying risk factors. Support (if any) NA
651 Longitudinal, unobtrusive, and ecologically valid sleep metric estimation from a smart bed to predict the pathology of COVID-19
Garcia, Gary, Siyahjani, Farzad, Monette, Kevin, DeFranco, Susan , Sikri, Deepika, Chung, Johnny, Cauter, Eve Van , Guzenko, Dmytro , Somers, Virend K. , Mushtaq, Faisal

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A255-A255

10.1093/sleep/zsab072.649 Get It

Abstract Introduction Pathophysiologic responses to viral respiratory challenges such as SARS-CoV-2 may affect sleep duration, quality and concomitant cardiorespiratory function. Unobtrusive and ecologically valid methods to monitor longitudinal sleep metrics may therefore have practical value for surveillance and monitoring of infectious illnesses. We leveraged sleep metrics from Sleep Number 360 smart bed users to build a COVID-19 predictive model. Methods An IRB approved survey was presented to opting-in users from August to November 2020. COVID-19 test results were reported by 2003/6878 respondents (116 positive; 1887 negative). From the positive group, data from 82 responders (44.7±11.3 yrs.) who reported the date of symptom onset were used. From the negative group, data from 1519 responders (48.4±12.9 yrs.) who reported testing dates were used. Sleep duration, sleep quality, restful sleep duration, time to fall asleep, respiration rate, heart rate, and motion level were obtained from ballistocardiography signals stored in the cloud. Data from January to October 2020 were considered. The predictive model consists of two levels: 1) the daily probability of staying healthy calculated by logistic regression and 2) a continuous density Hidden Markov Model to refine the daily prediction considering the past decision history. Results With respect to their baseline, significant increases in sleep duration, average breathing rate, average heart rate and decrease in sleep quality were associated with symptom exacerbation in COVID-19 positive respondents. In COVID-19 negative respondents, no significant sleep or cardiorespiratory metrics were observed. Evaluation of the predictive model resulted in cross-validated area under the receiving-operator curve (AUC) estimate of 0.84±0.09 which is similar to values reported for wearable-sensors. Considering additional days to confirm prediction improved the AUC estimate to 0.93±0.05. Conclusion The results obtained on the smart bed user population suggest that unobtrusive sleep metrics may offer rich information to predict and track the development of symptoms in individuals infected with COVID-19. Support (if any):
744 Correlates to improvement in sleep in acute mania
Golebiowski, Raphael, Mansukhani, Meghna P. , Kolla, Bhanu Prakash

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A290-A290

10.1093/sleep/zsab072.741 Get It

Abstract Introduction Sleep disruption and reduced sleep duration are potential triggers and also core symptoms of a manic episode. Our understanding of how sleep duration changes during the course of a manic episode and its potential association with symptom improvement is limited. We examined the natural course of sleep duration and its association with time to discharge and other clinical and demographic factors in patients with mania. Methods This was a retrospective study conducted in patients admitted to an acute care psychiatric unit with a manic episode. Sleep duration was determined based on observer report as logged by nursing staff. Sleep duration at admission and discharge were determined by averaging the total sleep time on day 2/3 of hospitalization and day 3/2 preceding discharge date. We obtained data on possible confounders including antipsychotic (chlorpromazine equivalents), benzodiazepine (diazepam equivalents) and other hypnotic medication doses administered at admission and discharge. We examined the associations between the change in sleep duration from admission to discharge with length of hospitalization and other clinical and demographic characteristics. Results The sample consisted of 35 patients (54.3% male) aged 32 ± 9.96 years with an average length of hospitalization of 20.63 ± 18.62 days. The mean sleep duration on admission was 6.23 ± 1.77 hours and was 7.45 ± 1.49 hours on discharge, with a mean change of 1.23 ± 1.93 hours. The change in sleep duration was positively correlated with length of hospitalization (r=0.42; p=0.01). Other clinical factors including benzodiazepine or antipsychotic dose on admission, age, sex, and use of mood stabilizers were not correlated with the change in sleep duration. Conclusion There was a substantial improvement in the total sleep duration in patients with mania over the course of hospitalization. Overall, the change in sleep duration was only correlated to the length of stay and did not appear to be impacted by other clinical and demographic characteristics. Support (if any):
611 Sleep Disorders in a Longitudinal Community Cohort of Children with Down Syndrome
Patel, Nisha R. , Baughn, Julie , Morgenthaler, Timothy I.

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A240-A240

10.1093/sleep/zsab072.609 Get It

Abstract Introduction Obstructive sleep apnea (OSA) affects 50–79% of children with Down Syndrome (CDS) prompting the development of guidelines to increase early detection of OSA. Cross-sectional survey based data shows that CDS have higher rates of bedtime resistance, sleep anxiety, night waking and parasomnias, which are also under-recognized. However, due to increased survival of CDS it may be that OSA treated in childhood returns or worsens, or that CDS may develop other sleep disorders as their life experience and exposure to comorbidities expands. Little is known about sleep disorders across the life span of CDS and screening guidelines leave a gap beyond early childhood. We determined to enhance understanding of respiratory and non-respiratory sleep disorders in a community population of CDS. Methods A retrospective population based observational study of CDS born between 1995–2011 was performed using the Rochester Epidemiology Project database. Medical records from all encounters through July 2020 were reviewed to identify sleep disorders. Sleep diagnoses, sleep test results, and treatments aimed at sleep disorders were recorded. Results 94 CDS were identified with 85 providing consent for research. 54 out of 85 individuals were diagnosed with OSA with 26 diagnosed prior to age 4 and 25 undergoing polysomnography prior to treatment. 26 individuals underwent polysomnography following surgery of which 16 continued to have clinically significant OSA requiring further treatment with secondary surgery, CPAP or anti-inflammatory therapy. Other sleep disorders observed included insomnia (n=16), restless leg syndrome (n=7), periodic limb movement disorder (n=10), idiopathic hypersomnia (n=1), nightmares (n=1), nocturnal enuresis (n=1), bruxism (n=1) and delayed sleep phase disorder (n=1). Most non-OSA sleep disorders were diagnosed during OSA evaluation by sleep medicine providers. However, many children were on melatonin without a formal sleep disorder diagnosis. Conclusion Both OSA and other sleep disorders remain under-diagnosed in CDS. This may be due to lack of validated screening tools that can be administered at the primary care level. Screening recommendations should consider the longitudinal nature of OSA in CDS and the presence of non-respiratory sleep disorders. Adenotonsillectomy is not as effective in CDS and postsurgical polysomnography is warranted along with long term follow-up to assess for further treatment needs. Support (if any):
523 Characteristics of Patients with REM Sleep without Atonia/Periodic Limb Movements of Sleep without Dream Enactment Behaviors
Barker, Lina, Tippmann‐Peikert, Maja

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A206-A206

10.1093/sleep/zsab072.522 Get It

Abstract Introduction While REM sleep without atonia (RSWA) in REM sleep behavior disorder (RBD) is associated with male sex, age greater than or equal to 50 years, alpha-synucleinopathies, and narcolepsy, the characteristics of patients with RSWA/persistent periodic limb movements of sleep in REM sleep (RSWA/PLMS-REM) without dream enactment behaviors are unexplored. The aim of this study was to compare the demographics, comorbidities, and concomitant medication use between RSWA/PLMS-REM patients and non-RSWA/non-PLMS-REM controls. Based on anecdotal clinical observations, we hypothesized that these patients are more commonly young, women, have psychiatric or neurological diseases, and use antidepressants. Methods We conducted a retrospective review of the Mayo Clinic electronic medical record to identify all patients with RSWA/PLMS-REM between November 2018 and November 2020. After excluding all patients with RBD, restless legs syndrome, narcolepsy, and RSWA/non-PLMS-REM, we identified 27 patients. All in-lab polysomnograms (PSGs) were reviewed to calculate the periodic limb movement index per hour of REM sleep (REM-PLMI). We also identified a control group of 15 individuals without RSWA, reviewed their PSGs, and calculated the REM-PLMI. Results The mean REM-PLMI of patients with RSWA was 64 +/- 8.3 (standard error of mean (SEM)) per hour versus 1 +/- 0.6 (SEM) per hour in non-RSWA controls (p < 0.001). Patients with RSWA/PLMS-REM and non-RSWA controls had similar age and gender, 62 +/- 3 (SEM) versus 58 +/- 3 (SEM) years and 81% versus 87% men, respectively. However, psychiatric diagnosis, neurological disorders, and antidepressants use were more common among RSWA/PLMS-REM patients compared to non-RSWA controls with p = 0.0002, p = 0.0035 and p = 0.0074 respectively (Fisher’s Exact Test). Conclusion Psychiatric diagnosis, neurological disorders, and antidepressant use are more common among RSWA/PLMS-REM patients compared to non-RSWA/non-PLMS-REM controls. Further research to determine the implications of a diagnosis of RSWA/PLMS-REM for the future development of alpha-synucleinopathies are needed and currently ongoing. Support (if any):